CN
75-07-0
应用筛选条件
关键词:'75-07-0'
显示 1-11 共 11 条结果 关于 "75-07-0" 范围 论文
Christian Schoergenhofer et al.
European journal of clinical investigation, 47(7), 504-512 (2017-05-31)
Despite decades of clinical use, the pharmacokinetics and the effects of acetylsalicylic acid (ASA) in critically ill patients remain ill-defined. We aimed to investigate the pharmacokinetics and the effects of different ASA formulations during critical illness. A cross-sectional study and
Sushma Potti et al.
JSLS : Journal of the Society of Laparoendoscopic Surgeons, 16(4), 537-541 (2013-03-15)
We evaluated Novasure ablation as a mechanical endometrial preparation agent before Roller Ball endometrial ablation in lieu of GnRH agonists in large uteri. A retrospective chart review of 20 consecutive patients undergoing Novasure ablation for mechanical endometrial preparation before Roller
H Wang et al.
Clinical and experimental immunology, 181(3), 518-527 (2015-05-13)
The interaction between neutrophils and activation of alternative complement pathway plays a pivotal role in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCAs activate primed neutrophils to release neutrophil extracellular traps (NETs), which have recently gathered increasing attention
Sergio Amadori et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4424-4430 (2013-10-16)
This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients (n = 472) age 61 to 75 years were randomly assigned to induction
Masoud Movahedi et al.
Iranian journal of allergy, asthma, and immunology, 7(4), 215-220 (2008-12-05)
Asthma is a complex and multifactorial disorder. Several studies have reported association between different HLA- DQB1 and HLA- DRB1 alleles and allergic asthma. The aim of the present study was to investigate the association of HLA-class II alleles and haplotypes
Lei Gao et al.
The Lancet. Infectious diseases, 17(10), 1053-1061 (2017-07-19)
The management of latent Mycobacterium tuberculosis infection is a new priority action for the WHO End Tuberculosis (TB) Strategy. However, national guidelines on latent tuberculosis infection testing and treatment have not yet been developed in China. Here, we present the
Ajay K Gopal et al.
Blood, 113(23), 5905-5910 (2009-04-01)
Radioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) are limited. We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL. CD45 was highly expressed on hT-NHL patient samples (median, 2.3 x 10(5) antigen-binding capacity units/cell) and hT-NHL cell lines (3.4
The Lancet. Neurology, 14(1), 39-47 (2014-12-04)
PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington's disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington's
Elise Cuyvers et al.
The Lancet. Neurology, 14(8), 814-822 (2015-07-05)
ABCA7 was identified as a risk gene for Alzheimer's disease in genome-wide association studies (GWAS). It was one of the genes most strongly associated with risk of Alzheimer's disease in a Belgian cohort. Using targeted resequencing, we investigated ABCA7 in
Annemiek Broyl et al.
The Lancet. Oncology, 11(11), 1057-1065 (2010-09-25)
Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two or three treatment
Siham Sikander et al.
The lancet. Psychiatry, 6(2), 128-139 (2019-01-29)
The Thinking Healthy Programme (THP), which is endorsed by WHO, is an evidence-based intervention for perinatal depression. We adapted THP for delivery by volunteer peers (laywomen from the community) to address the human resource needs in bridging the treatment gap
1/1